FDA launches pilot to boost US manufacturing of animal drugs

The FDA's Center for Veterinary Medicine (CVM) has launched a pilot program aimed at encouraging and strengthening domestic manufacturing of animal drug products and their active ingredients.¹ According to the FDA, the initiative reflects CVM's commitment to supporting a resilient veterinary pharmaceutical supply chain, preventing animal drug shortages, and advancing the agency's broader effort to increase American pharmaceutical manufacturing.¹

Like its human-drug counterpart, the veterinary pharmaceutical supply chain relies significantly on active ingredients and finished products manufactured outside the US.¹ That dependence can leave the supply of animal drugs vulnerable to disruption. The new pilot is intended to reduce that risk by prioritizing reviews of animal drug applications in which both the finished drug product and the active ingredient(s) are manufactured domestically.¹

The program offers 2 primary incentives for eligible sponsors, according to the FDA¹:

• Priority review consideration for complete Chemistry, Manufacturing and Controls technical sections: Sponsors may receive priority review consideration for complete Chemistry, Manufacturing and Controls (CMC) technical sections when both the finished drug product and its active ingredient(s) are manufactured in the US.
• Review of a second domestic active ingredient source in the original submission: Eligible sponsors may include a second domestic source of active ingredient up front as part of an original application or technical section submission, provided at least 1 of the sources is domestically manufactured. This eliminates the need to submit a post-approval supplemental application.

By allowing sponsors to build a second domestic ingredient source into the initial submission, the FDA noted, the program is designed to spare companies the added step of filing a supplemental application after approval—an approach that could give manufacturers more flexibility and help safeguard supply continuity.¹

Modeled on human-drug efforts

The animal drug domestic manufacturing pilot is modeled on approaches already implemented by the FDA's Center for Drug Evaluation and Research, including its ANDA Prioritization Pilot, and adapts those frameworks for animal drugs.¹ It is part of the agency's wider set of actions intended to support and strengthen domestic drug manufacturing.¹

CVM said it intends to monitor the pilot's effectiveness and may provide additional information or modify the program based on stakeholder experience and feedback.¹

Interested sponsors can find eligibility details and information on how to contact the Division of Manufacturing Technologies, housed within CVM's Office of Generic Animal Drugs and Office of New Animal Product Evaluation through the agency's CVM Pilot Program webpage.¹

Reference

FDA launches pilot program to incentivize manufacturing of animal drug products in the U.S. US Food and Drug Administration. July 21, 2026. Accessed July 21, 2026. https://www.fda.gov/animal-veterinary/cvm-updates/fda-launches-pilot-program-incentivize-manufacturing-animal-drug-products-us